Form 4: Amylyx Pharmaceuticals Co-CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On March 3, 2025, Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 4,595 shares of common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $3.1663, with individual transactions ranging from $3.09 to $3.195.
- Following the transaction, Cohen directly owns 3,196,652 shares of Amylyx Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction is a routine part of executive compensation and does not necessarily indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the share sale transaction. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.